{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:43:58Z","timestamp":1787024638611,"version":"build-2736575974"},"reference-count":155,"publisher":"Bentham Science Publishers Ltd.","issue":"29","funder":[{"DOI":"10.13039\/501100017599","name":"Science and Technology Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2018R01015"],"award-info":[{"award-number":["2018R01015"]}],"id":[{"id":"10.13039\/501100017599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877101"],"award-info":[{"award-number":["21877101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Provincial Natural Science Foundation of China","doi-asserted-by":"publisher","award":["LY19B020008"],"award-info":[{"award-number":["LY19B020008"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New-shoot Talents Program of Zhejiang Province","award":["2022R403081"],"award-info":[{"award-number":["2022R403081"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Janus Kinase (JAK), a nonreceptor protein tyrosine kinase, has emerged as an\nexcellent target through research and development since its discovery in the 1990s. As\nnovel small-molecule targeted drugs, JAK inhibitor drugs have been successfully used in\nthe treatment of rheumatoid arthritis (RA), myelofibrosis (MF), and ulcerative colitis\n(UC). With the gradual development of JAK targets in the market, JAK inhibitors have\nalso received considerable feedback in the treatment of autoimmune diseases, such as\natopic dermatitis (AD), Crohn's disease (CD), and graft-versus-host disease (GVHD).\nThis article reviews the research progress of JAK inhibitor drugs, focusing on the existing\nJAK inhibitors in the market and some JAK inhibitors in clinical trials currently. In addition,\nthe synthesis of various types of JAK inhibitors and the effects of different drug\nstructures on drug inhibition and selectivity are summarized.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1568026622666220307124142","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T01:27:03Z","timestamp":1646702823000},"page":"5010-5040","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of\nJAK Inhibitor Drugs"],"prefix":"10.2174","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-6004","authenticated-orcid":true,"given":"Min-Yan","family":"Zhao","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, and Institute of Drug Development\n&amp; Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, and Institute of Drug Development\n&amp; Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-7191","authenticated-orcid":true,"given":"Guo-Wu","family":"Rao","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, and Institute of Drug Development\n&amp; Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1329","volume":"5","author":"Firmbach-Kraft I.","year":"1990","unstructured":"Firmbach-Kraft I.; Byers M.; Shows T.; Dalla-Favera R.; Krolewski J.J.; tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 1990,5(9),1329-1336","journal-title":"Oncogene"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1128\/mcb.11.4.2057-2065.1991","volume":"11","author":"Wilks A.F.","year":"1991","unstructured":"Wilks A.F.; Harpur A.G.; Kurban R.R.; Ralph S.J.; Z\u00fcrcher G.; Ziemiecki A.; Two novel protein-tyrosine kinases, each with a sec-ond phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991,11(4),2057-2065","journal-title":"Mol Cell Biol"},{"key":"ref=3","first-page":"1347","volume":"7","author":"Harpur A.G.","year":"1992","unstructured":"Harpur A.G.; Andres A.C.; Ziemiecki A.; Aston R.R.; Wilks A.F.; JAK2, a third member of the JAK family of protein tyrosine ki-nases. Oncogene 1992,7(7),1347-1353","journal-title":"Oncogene"},{"key":"ref=4","first-page":"2415","volume":"9","author":"Rane S.G.","year":"1994","unstructured":"Rane S.G.; Reddy E.P.; JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994,9(8),2415-2423","journal-title":"Oncogene"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pep.2009.09.011","volume":"69","author":"Hall T.","year":"2010","unstructured":"Hall T.; Emmons T.L.; Chrencik J.E.; Gormley J.A.; Weinberg R.A.; Leone J.W.; Hirsch J.L.; Saabye M.J.; Schindler J.F.; Day J.E.; Williams J.M.; Kiefer J.R.; Lightle S.A.; Harris M.S.; Guru S.; Fischer H.D.; Tomasselli A.G.; Expression, purification, char-acterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain. Protein Expr Purif 2010,69(1),54-63","journal-title":"Protein Expr Purif"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nsmb.2099","volume":"18","author":"Ungureanu D.","year":"2011","unstructured":"Ungureanu D.; Wu J.; Pekkala T.; Niranjan Y.; Young C.; Jensen O.N.; Xu C.F.; Neubert T.A.; Skoda R.C.; Hubbard S.R.; Sil-vennoinen O.; The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011,18(9),971-976","journal-title":"Nat Struct Mol Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"8429","DOI":"10.1073\/pnas.90.18.8429","volume":"90","author":"Silvennoinen O.","year":"1993","unstructured":"Silvennoinen O.; Witthuhn B.A.; Quelle F.W.; Cleveland J.L.; Yi T.; Ihle J.N.; Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci USA 1993,90(18),8429-8433","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0092-8674(92)90504-6","volume":"71","author":"Pawson T.","year":"1992","unstructured":"Pawson T.; Gish G.D.; SH2 and SH3 domains: from structure to function. Cell 1992,71(3),359-362","journal-title":"Cell"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/366583a0","volume":"366","author":"Silvennoinen O.","year":"1993","unstructured":"Silvennoinen O.; Ihle J.N.; Schlessinger J.; Levy D.E.; Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature 1993,366(6455),583-585","journal-title":"Nature"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"15942","DOI":"10.1074\/jbc.270.27.15942","volume":"270","author":"Pallard C.","year":"1995","unstructured":"Pallard C.; Gouilleux F.; Charon M.; Groner B.; Gisselbrecht S.; Dusanter-Fourt I.; Interleukin-3, erythropoietin, and prolactin acti-vate a STAT5-like factor in lymphoid cells. J Biol Chem 1995,270(27),15942-15945","journal-title":"J Biol Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1002\/j.1460-2075.1994.tb06898.x","volume":"13","author":"Beadling C.","year":"1994","unstructured":"Beadling C.; Guschin D.; Witthuhn B.A.; Ziemiecki A.; Ihle J.N.; Kerr I.M.; Cantrell D.A.; Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes. EMBO J 1994,13(23),5605-5615","journal-title":"EMBO J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1182\/blood.V86.5.1671.bloodjournal8651671","volume":"86","author":"Wang Y.","year":"1995","unstructured":"Wang Y.; Morella K.K.; Ripperger J.; Lai C.F.; Gearing D.P.; Fey G.H.; Campos S.P.; Baumann H.; Receptors for interleukin-3 (IL-3) and growth hormone mediate an IL-6-type transcriptional induction in the presence of JAK2 or STAT3. Blood 1995,86(5),1671-1679","journal-title":"Blood"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117663","volume":"252","author":"Dong Y.","year":"2020","unstructured":"Dong Y.; Li X.; Yu Y.; Lv F.; Chen Y.; JAK\/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B. Life Sci 2020,252","journal-title":"Life Sci"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106439","volume":"83","author":"Le V\u00e9e M.","year":"2020","unstructured":"Le V\u00e9e M.; Bruy\u00e8re A.; Jouan E.; Fardel O.; Janus kinase-dependent regulation of drug detoxifying protein expression by interleukin-22 in human hepatic cells. Int Immunopharmacol 2020,83","journal-title":"Int Immunopharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/1043-2760(94)90096-5","volume":"5","author":"Ihle J.N.","year":"1994","unstructured":"Ihle J.N.; Signaling by the cytokine receptor superfamily just another kinase story. Trends Endocrinol Metab 1994,5(3),137-143","journal-title":"Trends Endocrinol Metab"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/0968-0004(94)90026-4","volume":"19","author":"Ihle J.N.","year":"1994","unstructured":"Ihle J.N.; Witthuhn B.A.; Quelle F.W.; Yamamoto K.; Thierfelder W.E.; Kreider B.; Silvennoinen O.; Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994,19(5),222-227","journal-title":"Trends Biochem Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1128\/mcb.14.7.4342-4349.1994","volume":"14","author":"Yamamoto K.","year":"1994","unstructured":"Yamamoto K.; Quelle F.W.; Thierfelder W.E.; Kreider B.L.; Gilbert D.J.; Jenkins N.A.; Copeland N.G.; Silvennoinen O.; Ihle J.N.; Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation. Mol Cell Biol 1994,14(7),4342-4349","journal-title":"Mol Cell Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"10738","DOI":"10.1074\/jbc.271.18.10738","volume":"271","author":"Lin J.X.","year":"1996","unstructured":"Lin J.X.; Mietz J.; Modi W.S.; John S.; Leonard W.J.; Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J Biol Chem 1996,271(18),10738-10744","journal-title":"J Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1016\/j.dci.2020.103749","volume":"111","author":"Liu L.K.","year":"2020","unstructured":"Liu L.K.; Chen X.X.; Gao R.L.; Wang K.J.; Zheng W.Y.; Liu H.P.; A cytokine receptor domeless promotes white spot syndrome virus infection via JAK\/STAT signaling pathway in red claw crayfish Cherax quadricarinatus. Dev Comp Immunol 2020,111","journal-title":"Dev Comp Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"Darnell J.E.J.","year":"1994","unstructured":"Darnell J.E.J.; Kerr I.M.; Stark G.R.; Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994,264(5164),1415-1421","journal-title":"Science"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.bi.64.070195.003201","volume":"64","author":"Schindler C.","year":"1995","unstructured":"Schindler C.; Darnell J.E.J.; Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995,64(1),621-651","journal-title":"Annu Rev Biochem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1523\/JNEUROSCI.13-07-03006.1993","volume":"13","author":"Yang X.","year":"1993","unstructured":"Yang X.; Chung D.; Cepko C.L.; Molecular cloning of the murine JAK1 protein tyrosine kinase and its expression in the mouse central nervous system. J Neurosci 1993,13(7),3006-3017","journal-title":"J Neurosci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.clim.2016.01.001","volume":"163","author":"Stepensky P.","year":"2016","unstructured":"Stepensky P.; Keller B.; Shamriz O.; NaserEddin, A.; Rumman, N.; Weintraub, M.; Warnatz, K.; Elpeleg, O.; Barak, Y. Deep intronic mis-splicing mutation in JAK3 gene underlies T\u2212B+NK\u2212 severe combined immunodeficiency phenotype. J Clin Immunol 2016,163,91-95","journal-title":"J Clin Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112155","volume":"192","author":"Xu P.","year":"2020","unstructured":"Xu P.; Shen P.; Yu B.; Xu X.; Ge R.; Cheng X.; Chen Q.; Bian J.; Li Z.; Wang J.; Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. Eur J Med Chem 2020,192","journal-title":"Eur J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.immuni.2020.07.006","volume":"53","author":"Gruber C.N.","year":"2020","unstructured":"Gruber C.N.; Calis J.J.A.; Buta S.; Evrony G.; Martin J.C.; Uhl S.A.; Caron R.; Jarchin L.; Dunkin D.; Phelps R.; Webb B.D.; Saland J.M.; Merad M.; Orange J.S.; Mace E.M.; Rosenberg B.R.; Gelb B.D.; Bogunovic D.; Complex autoinflammatory syndrome unveils fundamental principles of JAK1 Kinase Transcriptional and Biochemical Function. Immunity 2020,53(3),672-684.e11","journal-title":"Immunity"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"Levine R.L.","year":"2005","unstructured":"Levine R.L.; Wadleigh M.; Cools J.; Ebert B.L.; Wernig G.; Huntly B.J.P.; Boggon T.J.; Wlodarska I.; Clark J.J.; Moore S.; Ad-elsperger J.; Koo S.; Lee J.C.; Gabriel S.; Mercher T.; D\u2019Andrea A.; Fr\u00f6hling S.; D\u00f6hner K.; Marynen P.; Vandenberghe P.; Me-sa R.A.; Tefferi A.; Griffin J.D.; Eck M.J.; Sellers W.R.; Meyerson M.; Golub T.R.; Lee S.J.; Gilliland D.G.; Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005,7(4),387-397","journal-title":"Cancer Cell"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164080","volume":"11","author":"Alves de Medeiros A.K.","year":"2016","unstructured":"Alves de Medeiros A.K.; Speeckaert R.; Desmet E.; Van Gele M.; De Schepper S.; Lambert J.; JAK3 as an emerging target for topi-cal treatment of inflammatory skin diseases. PLoS One 2016,11(10)","journal-title":"PLoS One"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","volume":"41","author":"Luo W.","year":"2020","unstructured":"Luo W.; Li Y.X.; Jiang L.J.; Chen Q.; Wang T.; Ye D.W.; Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci 2020,41(8),531-543","journal-title":"Trends Pharmacol Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1021\/acsmedchemlett.8b00445","volume":"10","author":"Lightfoot H.L.","year":"2018","unstructured":"Lightfoot H.L.; Goldberg F.W.; Sedelmeier J.; Evolution of Small Molecule Kinase Drugs. ACS Med Chem Lett 2018,10(2),153-160","journal-title":"ACS Med Chem Lett"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"Clark J.D.","year":"2014","unstructured":"Clark J.D.; Flanagan M.E.; Telliez J.B.; Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014,57(12),5023-5038","journal-title":"J Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/14728214.2018.1444750","volume":"23","author":"Iorizzo M.","year":"2018","unstructured":"Iorizzo M.; Tosti A.; Emerging drugs for alopecia areata: JAK inhibitors. Expert Opin Emerg Drugs 2018,23(1),77-81","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.jaad.2017.12.019","volume":"78","author":"Cotter D.G.","year":"2018","unstructured":"Cotter D.G.; Schairer D.; Eichenfield L.; Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol 2018,78(3)(Suppl. 1),S53-S62","journal-title":"J Am Acad Dermatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.humimm.2016.12.005","volume":"78","author":"Moore C.A.","year":"2017","unstructured":"Moore C.A.; Iasella C.J.; Venkataramanan R.; Lakkis F.G.; Smith R.B.; McDyer J.F.; Zeevi A.; Ensor C.R.; Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges? Hum Immunol 2017,78(2),64-71","journal-title":"Hum Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","volume":"18","author":"Sarzi-Puttini P.","year":"2019","unstructured":"Sarzi-Puttini P.; Ceribelli A.; Marotto D.; Batticciotto A.; Atzeni F.; Systemic rheumatic diseases: From biological agents to small molecules. Autoimmun Rev 2019,18(6),583-592","journal-title":"Autoimmun Rev"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"Przepiorka D.","year":"2020","unstructured":"Przepiorka D.; Luo L.; Subramaniam S.; Qiu J.; Gudi R.; Cunningham L.C.; Nie L.; Leong R.; Ma L.; Sheth C.; Deisseroth A.; Goldberg K.B.; Blumenthal G.M.; Pazdur R.; FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist 2020,25(2),e328-e334","journal-title":"Oncologist"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10637-019-00812-5","volume":"38","author":"Machado-Neto J.A.","year":"2020","unstructured":"Machado-Neto J.A.; Coelho-Silva J.L.; Santos F.P.S.; Scheucher P.S.; Campregher P.V.; Hamerschlak N.; Rego E.M.; Traina F.; Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Invest New Drugs 2020,38(3),733-745","journal-title":"Invest New Drugs"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"Quint\u00e1s-Cardama A.","year":"2010","unstructured":"Quint\u00e1s-Cardama A.; Vaddi K.; Liu P.; Manshouri T.; Li J.; Scherle P.A.; Caulder E.; Wen X.; Li Y.; Waeltz P.; Rupar M.; Burn T.; Lo Y.; Kelley J.; Covington M.; Shepard S.; Rodgers J.D.; Haley P.; Kantarjian H.; Fridman J.S.; Verstovsek S.; Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neo-plasms. Blood 2010,115(15),3109-3117","journal-title":"Blood"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/cancers12082278","volume":"12","author":"Kuykendall A.T.","year":"2020","unstructured":"Kuykendall A.T.; Horvat N.P.; Pandey G.; Komrokji R.; Reuther G.W.; Finding a Jill for JAK: Assessing past, present, and future jak inhibitor combination approaches in myelofibrosis. Cancers (Basel) 2020,12(8),2278","journal-title":"Cancers (Basel)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00277-019-03727-6","volume":"98","author":"Breccia M.","year":"2019","unstructured":"Breccia M.; Luciano L.; Pugliese N.; Rossi E.; Tiribelli M.; Scalzulli E.; Bonifacio M.; Martino B.; Latagliata R.; Benevolo G.; Caocci G.; Binotto G.; Martinelli V.; Cavo M.; Pane F.; De Stefano V.; Fo\u00e0 R.; Palandri F.; Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. Ann Hematol 2019,98(8),1933-1936","journal-title":"Ann Hematol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41409-020-0952-z","volume":"55","author":"Modemann F.","year":"2020","unstructured":"Modemann F.; Ayuk F.; Wolschke C.; Christopeit M.; Janson D.; von Pein U.M.; Kr\u00f6ger N.; Ruxolitinib plus extracorporeal pho-topheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level. Bone Marrow Transplant 2020,55(12),2286-2293","journal-title":"Bone Marrow Transplant"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1124\/dmd.110.033787","volume":"38","author":"Shilling A.D.","year":"2010","unstructured":"Shilling A.D.; Nedza F.M.; Emm T.; Diamond S.; McKeever E.; Punwani N.; Williams W.; Arvanitis A.; Galya L.G.; Li M.; Shepard S.; Rodgers J.; Yue T.Y.; Yeleswaram S.; Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans. Drug Metab Dispos 2010,38(11),2023-2031","journal-title":"Drug Metab Dispos"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"Rosmarin D.","year":"2020","unstructured":"Rosmarin D.; Pandya A.G.; Lebwohl M.; Grimes P.; Hamzavi I.; Gottlieb A.B.; Butler K.; Kuo F.; Sun K.; Ji T.; Howell M.D.; Harris J.E.; Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet 2020,396(10244),110-120","journal-title":"Lancet"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","volume":"76","author":"Rothstein B.","year":"2017","unstructured":"Rothstein B.; Joshipura D.; Saraiya A.; Abdat R.; Ashkar H.; Turkowski Y.; Sheth V.; Huang V.; Au S.C.; Kachuk C.; Dumont N.; Gottlieb A.B.; Rosmarin D.; Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 2017,76(6),1054-1060.e1","journal-title":"J Am Acad Dermatol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1021\/ol900350k","volume":"11","author":"Lin Q.","year":"2009","unstructured":"Lin Q.; Meloni D.; Pan Y.; Xia M.; Rodgers J.; Shepard S.; Li M.; Galya L.; Metcalf B.; Yue T.Y.; Liu P.; Zhou J.; Enantioselec-tive synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org Lett 2009,11(9),1999-2002","journal-title":"Org Lett"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"Meyer D.M.","year":"2010","unstructured":"Meyer D.M.; Jesson M.I.; Li X.; Elrick M.M.; Funckes-Shippy C.L.; Warner J.D.; Gross C.J.; Dowty M.E.; Ramaiah S.K.; Hirsch J.L.; Saabye M.J.; Barks J.L.; Kishore N.; Morris D.L.; Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010,7(1),41","journal-title":"J Inflamm (Lond)"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/01.TP.0000157117.30290.6F","volume":"79","author":"Borie D.C.","year":"2005","unstructured":"Borie D.C.; Changelian P.S.; Larson M.J.; Si M.S.; Paniagua R.; Higgins J.P.; Holm B.; Campbell A.; Lau M.; Zhang S.; Flores M.G.; Rousvoal G.; Hawkins J.; Ball D.A.; Kudlacz E.M.; Brissette W.H.; Elliott E.A.; Reitz B.A.; Morris R.E.; Immunosuppres-sion by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005,79(7),791-801","journal-title":"Transplantation"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1021\/acsomega.9b02800","volume":"5","author":"Sanachai K.","year":"2020","unstructured":"Sanachai K.; Mahalapbutr P.; Choowongkomon K.; Poo-Arporn R.P.; Wolschann P.; Rungrotmongkol T.; Insights into the binding recognition and susceptibility of Tofacitinib toward Janus Kinases. ACS Omega 2020,5(1),369-377","journal-title":"ACS Omega"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1089\/ten.tea.2013.0553","volume":"20","author":"van Beuningen H.M.","year":"2014","unstructured":"van Beuningen H.M.; de Vries-van Melle M.L.; Vitters E.L.; Schreurs W.; van den Berg W.B.; van Osch G.J.; van der Kraan P.M.; Inhibition of TAK1 and\/or JAK can rescue impaired chondrogenic differentiation of human mesenchymal stem cells in osteoarthritis-like conditions. Tissue Eng Part A 2014,20(15-16),2243-2252","journal-title":"Tissue Eng Part A"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","volume":"74","author":"Boyle D.L.","year":"2015","unstructured":"Boyle D.L.; Soma K.; Hodge J.; Kavanaugh A.; Mandel D.; Mease P.; Shurmur R.; Singhal A.K.; Wei N.; Rosengren S.; Kaplan I.; Krishnaswami S.; Luo Z.; Bradley J.; Firestein G.S.; The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015,74(6),1311-1316","journal-title":"Ann Rheum Dis"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001174","volume":"6","author":"Finckh A.","year":"2020","unstructured":"Finckh A.; Tellenbach C.; Herzog L.; Scherer A.; Moeller B.; Ciurea A.; von Muehlenen I.; Gabay C.; Kyburz D.; Brulhart L.; M\u00fcller R.; Hasler P.; Zufferey P.; Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open 2020,6(1)","journal-title":"RMD Open"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30005-0","volume":"7","author":"Cohen S.B.","year":"2019","unstructured":"Cohen S.B.; Pope J.; Haraoui B.; Irazoque-Palazuelos F.; Korkosz M.; Diehl A.; Keystone E.C.; Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b\/4, non-inferiority trial. Lancet Rheumatol 2019,7(2)","journal-title":"Lancet Rheumatol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.semarthrit.2018.07.006","volume":"48","author":"Kivitz A.J.","year":"2018","unstructured":"Kivitz A.J.; Cohen S.; Keystone E.; van Vollenhoven R.F.; Haraoui B.; Kaine J.; Fan H.; Connell C.A.; Bananis E.; Takiya L.; Fleischmann R.; A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum 2018,48(3),406-415","journal-title":"Semin Arthritis Rheum"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","volume":"77","author":"Merola J.F.","year":"2017","unstructured":"Merola J.F.; Elewski B.; Tatulych S.; Lan S.; Tallman A.; Kaur M.; Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2017,77(1),79-87.e1","journal-title":"J Am Acad Dermatol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"Bachelez H.","year":"2015","unstructured":"Bachelez H.; van de Kerkhof P.C.M.; Strohal R.; Kubanov A.; Valenzuela F.; Lee J.H.; Yakusevich V.; Chimenti S.; Papa-charalambous J.; Proulx J.; Gupta P.; Tan H.; Tawadrous M.; Valdez H.; Wolk R.; Tofacitinib versus etanercept or placebo in mod-erate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial. Lancet 2015,386(9993),552-561","journal-title":"Lancet"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jaad.2016.07.040","volume":"75","author":"Feldman S.R.","year":"2016","unstructured":"Feldman S.R.; Tha\u00e7i D.; Gooderham M.; Augustin M.; de la Cruz C.; Mallbris L.; Buonanno M.; Tatulych S.; Kaur M.; Lan S.; Valdez H.; Mamolo C.; Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 2016,75(6),1162-1170.e3","journal-title":"J Am Acad Dermatol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","volume":"75","author":"Wu J.J.","year":"2016","unstructured":"Wu J.J.; Strober B.E.; Hansen P.R.; Ahlehoff O.; Egeberg A.; Qureshi A.A.; Robertson D.; Valdez H.; Tan H.; Wolk R.; Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. J Am Acad Dermatol 2016,75(5),897-905","journal-title":"J Am Acad Dermatol"},{"key":"ref=57","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106737","volume":"86","author":"Li Y.","year":"2020","unstructured":"Li Y.; Liu X.; Yu J.; Li Z.; Chen Y.; Li H.; Chen X.; Su W.; Liang D.; Tofacitinib suppresses mast cell degranulation and attenuates experimental allergic conjunctivitis. Int Immunopharmacol 2020,86","journal-title":"Int Immunopharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1600-6143.2008.02307.x","volume":"8","author":"van Gurp E.","year":"2008","unstructured":"van Gurp E.; Weimar W.; Gaston R.; Brennan D.; Mendez R.; Pirsch J.; Swan S.; Pescovitz M.D.; Ni G.; Wang C.; Krishnaswa-mi S.; Chow V.; Chan G.; Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 2008,8(8),1711-1718","journal-title":"Am J Transplant"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jdv.15937","volume":"34","author":"Guo L.","year":"2020","unstructured":"Guo L.; Feng S.; Sun B.; Jiang X.; Liu Y.; Guo L.; Feng S.; Liu Y.; Guo L.; Feng S.; Liu Y.; Liu Y.; Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 2020,34(1),192-201","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.14740\/jocmr4037","volume":"12","author":"Tanida S.","year":"2020","unstructured":"Tanida S.; Ozeki K.; Mizoshita T.; Kitagawa M.; Ozeki T.; Tanaka M.; Nishie H.; Shimura T.; Kubota E.; Kataoka H.; Combina-tion therapy with tofacitinib plus intensive granulocyte and monocyte adsorptive apheresis as induction therapy for refractory ulcerative colitis. J Clin Med Res 2020,12(1),36-40","journal-title":"J Clin Med Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","volume":"385","author":"Guimar\u00e3es P.O.","year":"2021","unstructured":"Guimar\u00e3es P.O.; Quirk D.; Furtado R.H.; Maia L.N.; Saraiva J.F.; Antunes M.O.; Kalil Filho R.; Junior V.M.; Soeiro A.M.; Tognon A.P.; Veiga V.C.; Martins P.A.; Moia D.D.F.; Sampaio B.S.; Assis S.R.L.; Soares R.V.P.; Piano L.P.A.; Castilho K.; Momesso R.G.R.A.P.; Monfardini F.; Guimar\u00e3es H.P.; Ponce de Leon D.; Dulcine M.; Pinheiro M.R.T.; Gunay L.M.; Deuring J.J.; Rizzo L.V.; Koncz T.; Berwanger O.; Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021,385(5),406-415","journal-title":"N Engl J Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1021\/acs.chemrestox.9b00141","volume":"32","author":"Guo X.","year":"2019","unstructured":"Guo X.; Li W.; Li Q.; Chen Y.; Zhao G.; Peng Y.; Zheng J.; Zheng J.; Tofacitinib is a mechanism-based inactivator of Cytochrome P450 3A4. Chem Res Toxicol 2019,32(9),1791-1800","journal-title":"Chem Res Toxicol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1016\/j.tetlet.2013.07.042","volume":"54","author":"Adolfo M.","year":"2013","unstructured":"Adolfo M.; Mario J.S.; Leonardo S.S.; Asymmetric total synthesis of Tofacitinib. Tetrahedron Lett 2013,54(37),5096-5098","journal-title":"Tetrahedron Lett"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"Fridman J.S.","year":"2010","unstructured":"Fridman J.S.; Scherle P.A.; Collins R.; Burn T.C.; Li Y.; Li J.; Covington M.B.; Thomas B.; Collier P.; Favata M.F.; Wen X.; Shi J.; McGee R.; Haley P.J.; Shepard S.; Rodgers J.D.; Yeleswaram S.; Hollis G.; Newton R.C.; Metcalf B.; Friedman S.M.; Vaddi K.; Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010,184(9),5298-5307","journal-title":"J Immunol"},{"key":"ref=65","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106748","volume":"86","author":"d\u2019Alessandro M.","year":"2020","unstructured":"d\u2019Alessandro M.; Perillo F.; Metella Refini R.; Bergantini L.; Bellisai F.; Selvi E.; Cameli P.; Manganelli S.; Conticini E.; Canta-rini L.; Sestini P.; Frediani B.; Bargagli E.; Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and in-flammatory biomarkers in a real-life setting. Int Immunopharmacol 2020,86","journal-title":"Int Immunopharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/cells8101276","volume":"8","author":"Liu C.","year":"2019","unstructured":"Liu C.; Arnold R.; Henriques G.; Djabali K.; Inhibition of JAK-STAT signaling with baricitinib reduces inflammation and improves cellular homeostasis in progeria cells. Cells 2019,8(10),1276","journal-title":"Cells"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"Keystone E.C.","year":"2015","unstructured":"Keystone E.C.; Taylor P.C.; Drescher E.; Schlichting D.E.; Beattie S.D.; Berclaz P.Y.; Lee C.H.; Fidelus-Gort R.K.; Luchi M.E.; Rooney T.P.; Macias W.L.; Genovese M.C.; Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015,74(2),333-340","journal-title":"Ann Rheum Dis"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"Simpson E.L.","year":"2020","unstructured":"Simpson E.L.; Lacour J.P.; Spelman L.; Galimberti R.; Eichenfield L.F.; Bissonnette R.; King B.A.; Thyssen J.P.; Silverberg J.I.; Bieber T.; Kabashima K.; Tsunemi Y.; Costanzo A.; Guttman-Yassky E.; Beck L.A.; Janes J.M.; DeLozier A.M.; Gamalo M.; Brinker D.R.; Cardillo T.; Nunes F.P.; Paller A.S.; Wollenberg A.; Reich K.; Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: Results from two randomized monotherapy phase III trials. Br J Dermatol 2020,183(2),242-255","journal-title":"Br J Dermatol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"Guttman-Yassky E.","year":"2019","unstructured":"Guttman-Yassky E.; Silverberg J.I.; Nemoto O.; Forman S.B.; Wilke A.; Prescilla R.; de la Pe\u00f1a A.; Nunes F.P.; Janes J.; Gama-lo M.; Donley D.; Paik J.; DeLozier A.M.; Nickoloff B.J.; Simpson E.L.; Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 2019,80(4),913-921.e9","journal-title":"J Am Acad Dermatol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"Shi J.G.","year":"2014","unstructured":"Shi J.G.; Chen X.; Lee F.; Emm T.; Scherle P.A.; Lo Y.; Punwani N.; Williams W.V.; Yeleswaram S.; The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J Clin Pharmacol 2014,54(12),1354-1361","journal-title":"J Clin Pharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","volume":"2","author":"Jabbari A.","year":"2015","unstructured":"Jabbari A.; Dai Z.; Xing L.; Cerise J.E.; Ramot Y.; Berkun Y.; Sanchez G.A.; Goldbach-Mansky R.; Christiano A.M.; Clynes R.; Zlotogorski A.; Clynes R.; Reversal of Alopecia areata following treatment with the JAK1\/2 inhibitor Baricitinib. EBioMedicine 2015,2(4),351-355","journal-title":"EBioMedicine"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","volume":"40","author":"Jorgensen S.C.J.","year":"2020","unstructured":"Jorgensen S.C.J.; Tse C.L.Y.; Burry L.; Dresser L.D.; Baricitinib: A review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy 2020,40(8),843-856","journal-title":"Pharmacotherapy"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"Wallace D.J.","year":"2018","unstructured":"Wallace D.J.; Furie R.A.; Tanaka Y.; Kalunian K.C.; Mosca M.; Petri M.A.; D\u00f6rner T.; Cardiel M.H.; Bruce I.N.; Gomez E.; Carmack T.; DeLozier A.M.; Janes J.M.; Linnik M.D.; de Bono S.; Silk M.E.; Hoffman R.W.; Baricitinib for systemic lupus ery-thematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018,392(10143),222-231","journal-title":"Lancet"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3184\/174751916X14569294811333","volume":"40","author":"Xu J.J.","year":"2016","unstructured":"Xu J.J.; Cai J.; Chen J.D.; Zong X.; Wu X.; Ji M.; Wang P.; An efficient synthesis of baricitinib. J Chem Res 2016,40(4),205-208","journal-title":"J Chem Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jcph.1513","volume":"60","author":"Mohamed M.F.","year":"2020","unstructured":"Mohamed M.F.; Beck D.; Camp H.S.; Othman A.A.; Preferential inhibition of JAK1 relative to JAK3 by Upadacitinib: Exposure-response analyses of ex vivo data from 2 Phase 1 Clinical Trials and comparison to Tofacitinib. J Clin Pharmacol 2020,60(2),188-197","journal-title":"J Clin Pharmacol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/art.39801","volume":"68","author":"Kremer J.M.","year":"2016","unstructured":"Kremer J.M.; Emery P.; Camp H.S.; Friedman A.; Wang L.; Othman A.A.; Khan N.; Pangan A.L.; Jungerwirth S.; Keystone E.C.; A Phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol 2016,68(12),2867-2877","journal-title":"Arthritis Rheumatol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/art.39808","volume":"68","author":"Genovese M.C.","year":"2016","unstructured":"Genovese M.C.; Smolen J.S.; Weinblatt M.E.; Burmester G.R.; Meerwein S.; Camp H.S.; Wang L.; Othman A.A.; Khan N.; Pan-gan A.L.; Jungerwirth S.; Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a Phase IIb Study in patients with rheumatoid arthritis and an inadequate response to Methotrexate. Arthritis Rheumatol 2016,68(12),2857-2866","journal-title":"Arthritis Rheumatol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"Sandborn W.J.","year":"2020","unstructured":"Sandborn W.J.; Feagan B.G.; Loftus E.V.J.; Peyrin-Biroulet L.; Van Assche G.; D\u2019Haens G.; Schreiber S.; Colombel J.F.; Lewis J.D.; Ghosh S.; Armuzzi A.; Scherl E.; Herfarth H.; Vitale L.; Mohamed M.F.; Othman A.A.; Zhou Q.; Huang B.; Thak-kar R.B.; Pangan A.L.; Lacerda A.P.; Panes J.; efficacy and safety of Upadacitinib in a randomized trial of patients with Crohn\u2019s Dis-ease. Gastroenterology 2020,158(8),2123-2138.e8","journal-title":"Gastroenterology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcph.1550","volume":"60","author":"Nader A.","year":"2020","unstructured":"Nader A.; Stodtmann S.; Friedel A.; Mohamed M.F.; Othman A.A.; Pharmacokinetics of Upadacitinib in healthy subjects and sub-jects with rheumatoid arthritis, Crohn\u2019s disease, ulcerative colitis, or atopic dermatitis: Population analyses of Phase 1 and 2 clinical tri-als. J Clin Pharmacol 2020,60(4),528-539","journal-title":"J Clin Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"Sandborn W.J.","year":"2020","unstructured":"Sandborn W.J.; Ghosh S.; Panes J.; Schreiber S.; D\u2019Haens G.; Tanida S.; Siffledeen J.; Enejosa J.; Zhou W.; Othman A.A.; Huang B.; Higgins P.D.R.; Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 2020,158(8),2139-2149.e14","journal-title":"Gastroenterology"},{"key":"ref=81","author":"Zheng X.C.","year":"2018","unstructured":"Zheng X.C.; Zhang Y.P.; Fu C.C.; Wu Y.H.; Method for synthesizing upadacitinib. 2018"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","volume":"13","author":"Geron I.","year":"2008","unstructured":"Geron I.; Abrahamsson A.E.; Barroga C.F.; Kavalerchik E.; Gotlib J.; Hood J.D.; Durocher J.; Mak C.C.; Noronha G.; Soll R.M.; Tefferi A.; Kaushansky K.; Jamieson C.H.M.; Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008,13(4),321-330","journal-title":"Cancer Cell"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3389\/fphar.2018.01214","volume":"9","author":"Chen D.","year":"2018","unstructured":"Chen D.; Zhang F.; Wang J.; He H.; Duan S.; Zhu R.; Chen C.; Yin L.; Chen Y.; Biodegradable nanoparticles mediated co-delivery of erlotinib (ELTN) and fedratinib (FDTN) toward the treatment of ELTN-resistant non-small cell lung cancer (NSCLC) via suppression of the JAK2\/STAT3 signaling pathway. Front Pharmacol 2018,9,1214","journal-title":"Front Pharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","volume":"13","author":"Wernig G.","year":"2008","unstructured":"Wernig G.; Kharas M.G.; Okabe R.; Moore S.A.; Leeman D.S.; Cullen D.E.; Gozo M.; McDowell E.P.; Levine R.L.; Doukas J.; Mak C.C.; Noronha G.; Martin M.; Ko Y.D.; Lee B.H.; Soll R.M.; Tefferi A.; Hood J.D.; Gilliland D.G.; Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008,13(4),311-320","journal-title":"Cancer Cell"},{"key":"ref=85","first-page":"1540","volume":"39","author":"Liu H.C.","year":"2018","unstructured":"Liu H.C.; Lu S.; Zhang Y.M.; Zhou W.N.; Yin L.F.; Zhu L.; Zhao J.N.; Lu T.; Chen Y.D.; Molecular dynamics simulation of the selectivity of Fedratinib complex with JAK2\/JAK3. Chem J Chin Univ 2018,39(7),1540-1548","journal-title":"Chem J Chin Univ"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00280-020-04084-2","volume":"85","author":"Ogasawara K.","year":"2020","unstructured":"Ogasawara K.; Smith W.B.; Xu C.; Yin J.; Palmisano M.; Krishna G.; Pharmacokinetics and tolerability of fedratinib, an oral, selec-tive Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. Cancer Chemother Pharmacol 2020,85(6),1109-1117","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-020-04121-0","volume":"86","author":"Ogasawara K.","year":"2020","unstructured":"Ogasawara K.; Xu C.; Kanamaluru V.; Siebers N.; Surapaneni S.; Ridoux L.; Palmisano M.; Krishna G.; Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects. Cancer Chemother Pharmacol 2020,86(2),307-314","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173238","volume":"882","author":"Emori T.","year":"2020","unstructured":"Emori T.; Kasahara M.; Sugahara S.; Hashimoto M.; Ito H.; Narumiya S.; Higashi Y.; Fujii Y.; Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib. Eur J Pharmacol 2020,882","journal-title":"Eur J Pharmacol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells8060561","volume":"8","author":"Ikari Y.","year":"2019","unstructured":"Ikari Y.; Isozaki T.; Tsubokura Y.; Kasama T.; Peficitinib Inhibits the chemotactic activity of monocytes via proinflammatory cytokine production in rheumatoid arthritis fibroblast-like synoviocytes. Cells 2019,8(6),561","journal-title":"Cells"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3389\/fimmu.2019.00541","volume":"10","author":"Diller M.","year":"2019","unstructured":"Diller M.; Hasseli R.; H\u00fclser M.L.; Aykara I.; Frommer K.; Rehart S.; M\u00fcller-Ladner U.; Neumann E.; Targeting activated synovial fibroblasts in rheumatoid arthritis by peficitinib. Front Immunol 2019,10,541","journal-title":"Front Immunol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","volume":"78","author":"Takeuchi T.","year":"2019","unstructured":"Takeuchi T.; Tanaka Y.; Tanaka S.; Kawakami A.; Iwasaki M.; Katayama K.; Rokuda M.; Izutsu H.; Ushijima S.; Kaneko Y.; Shiomi T.; Yamada E.; van der Heijde D.; Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an in-adequate response to methotrexate: Results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis 2019,78(10),1305-1319","journal-title":"Ann Rheum Dis"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/art.40054","volume":"69","author":"Genovese M.C.","year":"2017","unstructured":"Genovese M.C.; Greenwald M.; Codding C.; Zubrzycka-Sienkiewicz A.; Kivitz A.J.; Wang A.; Shay K.; Wang X.; Garg J.P.; Cardiel M.H.; Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol 2017,69(5),932-942","journal-title":"Arthritis Rheumatol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40261-020-00937-z","volume":"40","author":"Zhu T.","year":"2020","unstructured":"Zhu T.; Moy S.; Valluri U.; Cao Y.; Zhang W.; Sawamoto T.; Chindalore V.; Akinlade B.; Akinlade B.; Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis. Clin Drug Investig 2020,40(9),827-838","journal-title":"Clin Drug Investig"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40261-019-00873-7","volume":"40","author":"Miyatake D.","year":"2020","unstructured":"Miyatake D.; Shibata T.; Shibata M.; Kaneko Y.; Oda K.; Nishimura T.; Katashima M.; Sekino H.; Furihata K.; Urae A.; Pharma-cokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function. Clin Drug Investig 2020,40(2),149-159","journal-title":"Clin Drug Investig"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1016\/j.bmc.2018.08.005","volume":"26","author":"Hamaguchi H.","year":"2018","unstructured":"Hamaguchi H.; Amano Y.; Moritomo A.; Shirakami S.; Nakajima Y.; Nakai K.; Nomura N.; Ito M.; Higashi Y.; Inoue T.; Dis-covery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. Bioorg Med Chem 2018,26(18),4971-4983","journal-title":"Bioorg Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1248\/cpb.c15-00036","volume":"63","author":"Nakajima Y.","year":"2015","unstructured":"Nakajima Y.; Tojo T.; Morita M.; Hatanaka K.; Shirakami S.; Tanaka A.; Sasaki H.; Nakai K.; Mukoyoshi K.; Hamaguchi H.; Takahashi F.; Moritomo A.; Higashi Y.; Inoue T.; Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel im-munomodulators targeting Janus kinase 3. Chem Pharm Bull (Tokyo) 2015,63(5),341-353","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","volume":"64","author":"Tanimoto A.","year":"2015","unstructured":"Tanimoto A.; Ogawa Y.; Oki C.; Kimoto Y.; Nozawa K.; Amano W.; Noji S.; Shiozaki M.; Matsuo A.; Shinozaki Y.; Matsushita M.; Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res 2015,64(1),41-51","journal-title":"Inflamm Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","volume":"136","author":"Amano W.","year":"2015","unstructured":"Amano W.; Nakajima S.; Kunugi H.; Numata Y.; Kitoh A.; Egawa G.; Dainichi T.; Honda T.; Otsuka A.; Kimoto Y.; Yamamoto Y.; Tanimoto A.; Matsushita M.; Miyachi Y.; Kabashima K.; The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol 2015,136(3),667-677.e7","journal-title":"J Allergy Clin Immunol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","volume":"82","author":"Nakagawa H.","year":"2020","unstructured":"Nakagawa H.; Nemoto O.; Igarashi A.; Saeki H.; Kaino H.; Nagata T.; Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol 2020,82(4),823-831","journal-title":"J Am Acad Dermatol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","volume":"144","author":"Nakagawa H.","year":"2019","unstructured":"Nakagawa H.; Nemoto O.; Igarashi A.; Saeki H.; Oda M.; Kabashima K.; Nagata T.; Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol 2019,144(6),1575-1583","journal-title":"J Allergy Clin Immunol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/1346-8138.15173","volume":"47","author":"Nakagawa H.","year":"2020","unstructured":"Nakagawa H.; Nemoto O.; Igarashi A.; Saeki H.; Murata R.; Kaino H.; Nagata T.; Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol 2020,47(2),114-120","journal-title":"J Dermatol"},{"key":"ref=102","author":"Takiguchi H.","year":"2018","unstructured":"Takiguchi H.; Higashi A.; Inaba T.; Watanabe T.; Takeichi T.; Petersen A.K.; Vedsoe P.; Jensen K.L.; Bornholdt J.; Ebdrup S.; Process for preparation of 7Hpyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates.  2018"},{"key":"ref=103","author":"Xu X.N.","year":"2020","unstructured":"Xu X.N.; Preparation method of delgocitinib. 2020"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1021\/jm501262q","volume":"57","author":"Menet C.J.","year":"2014","unstructured":"Menet C.J.; Fletcher S.R.; Van Lommen G.; Geney R.; Blanc J.; Smits K.; Jouannigot N.; Deprez P.; van der Aar E.M.; Clement-Lacroix P.; Lepescheux L.; Galien R.; Vayssiere B.; Nelles L.; Christophe T.; Brys R.; Uhring M.; Ciesielski F.; Van Rompaey L.; Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem 2014,57(22),9323-9342","journal-title":"J Med Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mce.2017.11.016","volume":"472","author":"Wang Y.","year":"2018","unstructured":"Wang Y.; Chen L.; Xie L.; Li L.; Li X.; Li H.; Liu J.; Chen X.; Mao B.; Song T.; Lian Q.; Ge R.S.; Interleukin 6 inhibits the dif-ferentiation of rat stem Leydig cells. Mol Cell Endocrinol 2018,472,26-39","journal-title":"Mol Cell Endocrinol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","volume":"191","author":"Van Rompaey L.","year":"2013","unstructured":"Van Rompaey L.; Galien R.; van der Aar E.M.; Clement-Lacroix P.; Nelles L.; Smets B.; Lepescheux L.; Christophe T.; Conrath K.; Vandeghinste N.; Vayssiere B.; De Vos S.; Fletcher S.; Brys R.; van \u2019t Klooster G.; Feyen J.H.; Menet C.; Preclinical character-ization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013,191(7),3568-3577","journal-title":"J Immunol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s00393-019-00733-x","volume":"79","author":"Lee Y.H.","year":"2020","unstructured":"Lee Y.H.; Song G.G.; Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol 2020,79(6),590-603","journal-title":"Z Rheumatol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13075-018-1541-z","volume":"20","author":"Genovese M.","year":"2018","unstructured":"Genovese M.; Westhovens R.; Meuleners L.; Van der Aa A.; Harrison P.; Tasset C.; Kavanaugh A.; Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: Patient-reported outcomes. Arthritis Res Ther 2018,20(1),57","journal-title":"Arthritis Res Ther"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"Vermeire S.","year":"2017","unstructured":"Vermeire S.; Schreiber S.; Petryka R.; Kuehbacher T.; Hebuterne X.; Roblin X.; Klopocka M.; Goldis A.; Wisniewska-Jarosinska M.; Baranovsky A.; Sike R.; Stoyanova K.; Tasset C.; Van der Aa A.; Harrison P.; Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017,389(10066),266-275","journal-title":"Lancet"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/rheumatology\/kez408","volume":"59","author":"Orbai A.M.","year":"2020","unstructured":"Orbai A.M.; Ogdie A.; Gossec L.; Tillett W.; Leung Y.Y.; Gao J.; Trivedi M.; Tasset C.; Meuleners L.; Besuyen R.; Hendrikx T.; Coates L.C.; Effect of filgotinib on health-related quality of life in active psoriatic arthritis: A randomized phase 2 trial (EQUATOR). Rheumatology (Oxford) 2020,59(7),1495-1504","journal-title":"Rheumatology (Oxford)"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"van der Heijde D.","year":"2018","unstructured":"van der Heijde D.; Baraliakos X.; Gensler L.S.; Maksymowych W.P.; Tseluyko V.; Nadashkevich O.; Abi-Saab W.; Tasset C.; Meuleners L.; Besuyen R.; Hendrikx T.; Mozaffarian N.; Liu K.; Greer J.M.; Deodhar A.; Landew\u00e9 R.; Efficacy and safety of filgo-tinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): Results from a randomised, place-bo-controlled, phase 2 trial. Lancet 2018,392(10162),2378-2387","journal-title":"Lancet"},{"key":"ref=112","author":"Sathe D.G.","year":"2020","unstructured":"Sathe D.G.; Das A.; Patel B.; Kshirsagar E.; Patil D.; Matale A.; Novel process for the preparation of filgotinib and intermediates thereof. 2020"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"7195","DOI":"10.1021\/acs.jmedchem.5b00301","volume":"58","author":"Farmer L.J.","year":"2015","unstructured":"Farmer L.J.; Ledeboer M.W.; Hoock T.; Arnost M.J.; Bethiel R.S.; Bennani Y.L.; Black J.J.; Brummel C.L.; Chakilam A.; Dorsch W.A.; Fan B.; Cochran J.E.; Halas S.; Harrington E.M.; Hogan J.K.; Howe D.; Huang H.; Jacobs D.H.; Laitinen L.M.; Liao S.; Mahajan S.; Marone V.; Martinez-Botella G.; McCarthy P.; Messersmith D.; Namchuk M.; Oh L.; Penney M.S.; Pierce A.C.; Raybuck S.A.; Rugg A.; Salituro F.G.; Saxena K.; Shannon D.; Shlyakter D.; Swenson L.; Tian S.K.; Town C.; Wang J.; Wang T.; Wannamaker M.W.; Winquist R.J.; Zuccola H.J.; Discovery of VX-509 (Decernotinib): A potent and selective Janus Kinase 3 inhibitor for the treatment of autoimmune diseases. J Med Chem 2015,58(18),7195-7216","journal-title":"J Med Chem"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/jpet.114.221176","volume":"353","author":"Mahajan S.","year":"2015","unstructured":"Mahajan S.; Hogan J.K.; Shlyakhter D.; Oh L.; Salituro F.G.; Farmer L.; Hoock T.C.; VX-509 (decernotinib) is a potent and selec-tive janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther 2015,353(2),405-414","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/art.38949","volume":"67","author":"Fleischmann R.M.","year":"2015","unstructured":"Fleischmann R.M.; Damjanov N.S.; Kivitz A.J.; Legedza A.; Hoock T.; Kinnman N.; A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 2015,67(2),334-343","journal-title":"Arthritis Rheumatol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.39473","volume":"68","author":"Genovese M.C.","year":"2016","unstructured":"Genovese M.C.; van Vollenhoven R.F.; Pacheco-Tena C.; Zhang Y.; Kinnman N.; VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 2016,68(1),46-55","journal-title":"Arthritis Rheumatol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1124\/jpet.114.218164","volume":"351","author":"Coffey G.","year":"2014","unstructured":"Coffey G.; Betz A.; DeGuzman F.; Pak Y.; Inagaki M.; Baker D.C.; Hollenbach S.J.; Pandey A.; Sinha U.; The novel kinase inhib-itor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther 2014,351(3),538-548","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3892\/ijo.2018.4513","volume":"53","author":"Ishikawa C.","year":"2018","unstructured":"Ishikawa C.; Senba M.; Mori N.; Anti-adult T cell leukemia\/lymphoma activity of cerdulatinib, a dual SYK\/JAK kinase inhibitor. Int J Oncol 2018,53(4),1681-1690","journal-title":"Int J Oncol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1016-3190(10)60056-0","volume":"22","author":"Lai P.C.","year":"2010","unstructured":"Lai P.C.; Fang T.C.; Cheng C.C.; Chiu T.H.; Huang Y.T.; Lestaurtinib is cytotoxic to oxaliplatin-resistant transitional cell carcinoma cell Line T24 in vitro. Tzu-Chi Med J 2010,22(3),125-130","journal-title":"Tzu-Chi Med J"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1111\/jcmm.15415","volume":"24","author":"Cao Y.","year":"2020","unstructured":"Cao Y.; Kong S.; Xin Y.; Meng Y.; Shang S.; Qi Y.; Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction. J Cell Mol Med 2020,24(14),7829-7840","journal-title":"J Cell Mol Med"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207152","volume":"13","author":"Pinto N.","year":"2018","unstructured":"Pinto N.; Prokopec S.D.; Vizeacoumar F.; Searle K.; Lowerison M.; Ruicci K.M.; Yoo J.; Fung K.; MacNeil D.; Lacefield J.C.; Leong H.S.; Mymryk J.S.; Barrett J.W.; Datti A.; Boutros P.C.; Nichols A.C.; Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models. PLoS One 2018,13(11)","journal-title":"PLoS One"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","volume":"9","author":"Verstovsek S.","year":"2016","unstructured":"Verstovsek S.; Odenike O.; Singer J.W.; Granston T.; Al-Fayoumi S.; Deeg H.J.; Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol 2016,9(1),137","journal-title":"J Hematol Oncol"},{"key":"ref=123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222944","volume":"14","author":"Singer J.W.","year":"2019","unstructured":"Singer J.W.; Al-Fayoumi S.; Taylor J.; Velichko S.; O\u2019Mahony A.; Comparative phenotypic profiling of the JAK2 inhibitors rux-olitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. PLoS One 2019,14(9)","journal-title":"PLoS One"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1073\/pnas.1712452115","volume":"115","author":"Betts B.C.","year":"2018","unstructured":"Betts B.C.; Bastian D.; Iamsawat S.; Nguyen H.; Heinrichs J.L.; Wu Y.; Daenthanasanmak A.; Veerapathran A.; O\u2019Mahony A.; Walton K.; Reff J.; Horna P.; Sagatys E.M.; Lee M.C.; Singer J.; Chang Y.J.; Liu C.; Pidala J.; Anasetti C.; Yu X.Z.; Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci USA 2018,115(7),1582-1587","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jbspin.2015.09.002","volume":"83","author":"Wu H.","year":"2016","unstructured":"Wu H.; Yan S.; Chen J.; Luo X.; Li P.; Jia X.; Dai X.; Wang C.; Huang Q.; Liu L.; Zhang Y.; Zhou A.; Chang Y.; Zhang L.; Wei W.; JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells. Joint Bone Spine 2016,83(5),525-532","journal-title":"Joint Bone Spine"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3892\/ijmm.2016.2692","volume":"38","author":"Gu Y.J.","year":"2016","unstructured":"Gu Y.J.; Sun W.Y.; Zhang S.; Li X.R.; Wei W.; Targeted blockade of JAK\/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells. Int J Mol Med 2016,38(3),903-911","journal-title":"Int J Mol Med"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/leu.2011.175","volume":"25","author":"Monaghan K.A.","year":"2011","unstructured":"Monaghan K.A.; Khong T.; Burns C.J.; Spencer A.; The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, pre-vents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia 2011,25(12),1891-1899","journal-title":"Leukemia"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.3892\/or.2019.6970","volume":"41","author":"Liu T.","year":"2019","unstructured":"Liu T.; Li A.; Xu Y.; Xin Y.; Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2\/STAT3 inhibition. Oncol Rep 2019,41(3),1883-1892","journal-title":"Oncol Rep"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s10495-020-01607-3","volume":"25","author":"Cosenza M.","year":"2020","unstructured":"Cosenza M.; Civallero M.; Marcheselli L.; Sacchi S.; Pozzi S.; Citarinostat and Momelotinib co-target HDAC6 and JAK2\/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. Apoptosis 2020,25(5-6),370-387","journal-title":"Apoptosis"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.2017-0665","volume":"24","author":"Beatty G.L.","year":"2019","unstructured":"Beatty G.L.; Shahda S.; Beck T.; Uppal N.; Cohen S.J.; Donehower R.; Gabayan A.E.; Assad A.; Switzky J.; Zhen H.; Von Hoff D.D.; A Phase Ib\/II study of the JAK1 inhibitor, Itacitinib, plus nab-Paclitaxel and gemcitabine in advanced solid tumors. Oncologist 2019,24(1),14-e10","journal-title":"Oncologist"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"S186","DOI":"10.1016\/j.jid.2018.03.1111","volume":"138","author":"Dai Z.","year":"2018","unstructured":"Dai Z.; Zeng W.; Christiano A.M.; Efficacy of selective next-generation JAK inhibitors in the treatment of alopecia areata. J Invest Dermatol 2018,138(5),S186","journal-title":"J Invest Dermatol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/17512433.2020.1702878","volume":"13","author":"Ismail F.F.","year":"2020","unstructured":"Ismail F.F.; Sinclair R.; JAK inhibition in the treatment of alopecia areata - a promising new dawn? Expert Rev Clin Pharmacol 2020,13(1),43-51","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/art.41316","volume":"72","author":"Robinson M.F.","year":"2020","unstructured":"Robinson M.F.; Damjanov N.; Stamenkovic B.; Radunovic G.; Kivitz A.; Cox L.; Manukyan Z.; Banfield C.; Saunders M.; Chan-dra D.; Vincent M.S.; Mancuso J.; Peeva E.; Beebe J.S.; Efficacy and safety of PF-06651600 (Ritlecitinib), a novel JAK3\/TEC inhibi-tor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to Methotrexate. Arthritis Rheumatol 2020,72(10),1621-1631","journal-title":"Arthritis Rheumatol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/bcp.13612","volume":"84","author":"Peeva E.","year":"2018","unstructured":"Peeva E.; Hodge M.R.; Kieras E.; Vazquez M.L.; Goteti K.; Tarabar S.G.; Alvey C.W.; Banfield C.; Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. Br J Clin Pharmacol 2018,84(8),1776-1788","journal-title":"Br J Clin Pharmacol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjd.16004","volume":"179","author":"Schmieder G.J.","year":"2018","unstructured":"Schmieder G.J.; Draelos Z.D.; Pariser D.M.; Banfield C.; Cox L.; Hodge M.; Kieras E.; Parsons-Rich D.; Menon S.; Salganik M.; Page K.; Peeva E.; Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol 2018,179(1),54-62","journal-title":"Br J Dermatol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/13543784.2018.1492547","volume":"27","author":"D\u2019Amico F.","year":"2018","unstructured":"D\u2019Amico F.; Fiorino G.; Furfaro F.; Allocca M.; Danese S.; Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs 2018,27(7),595-599","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","volume":"60","author":"Thorarensen A.","year":"2017","unstructured":"Thorarensen A.; Dowty M.E.; Banker M.E.; Juba B.; Jussif J.; Lin T.; Vincent F.; Czerwinski R.M.; Casimiro-Garcia A.; Unwal-la R.; Trujillo J.I.; Liang S.; Balbo P.; Che Y.; Gilbert A.M.; Brown M.F.; Hayward M.; Montgomery J.; Leung L.; Yang X.; Soucy S.; Hegen M.; Coe J.; Langille J.; Vajdos F.; Chrencik J.; Telliez J.B.; Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the inter-rogation of JAK3 signaling in humans. J Med Chem 2017,60(5),1971-1993","journal-title":"J Med Chem"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1021\/acsmedchemlett.6b00247","volume":"7","author":"Liang X.","year":"2016","unstructured":"Liang X.; Zang J.; Zhu M.; Gao Q.; Wang B.; Xu W.; Zhang Y.; Design, synthesis, and antitumor evaluation of 4-Amino-(1H)-pyrazole derivatives as JAKs inhibitors. ACS Med Chem Lett 2016,7(10),950-955","journal-title":"ACS Med Chem Lett"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1021\/jm1011319","volume":"54","author":"Ioannidis S.","year":"2011","unstructured":"Ioannidis S.; Lamb M.L.; Wang T.; Almeida L.; Block M.H.; Davies A.M.; Peng B.; Su M.; Zhang H.J.; Hoffmann E.; Rivard C.; Green I.; Howard T.; Pollard H.; Read J.; Alimzhanov M.; Bebernitz G.; Bell K.; Ye M.; Huszar D.; Zinda M.; Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibi-tor of the Jak\/Stat pathway. J Med Chem 2011,54(1),262-276","journal-title":"J Med Chem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","volume":"61","author":"Fensome A.","year":"2018","unstructured":"Fensome A.; Ambler C.M.; Arnold E.; Banker M.E.; Brown M.F.; Chrencik J.; Clark J.D.; Dowty M.E.; Efremov I.V.; Flick A.; Gerstenberger B.S.; Gopalsamy A.; Hayward M.M.; Hegen M.; Hollingshead B.D.; Jussif J.; Knafels J.D.; Limburg D.C.; Lin D.; Lin T.H.; Pierce B.S.; Saiah E.; Sharma R.; Symanowicz P.T.; Telliez J.B.; Trujillo J.I.; Vajdos F.F.; Vincent F.; Wan Z.K.; Xing L.; Yang X.; Yang X.; Zhang L.; Dual Inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem 2018,61(19),8597-8612","journal-title":"J Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1021\/acs.jmedchem.9b01392","volume":"63","author":"Su Q.","year":"2020","unstructured":"Su Q.; Banks E.; Bebernitz G.; Bell K.; Borenstein C.F.; Chen H.; Chuaqui C.E.; Deng N.; Ferguson A.D.; Kawatkar S.; Grim-ster N.P.; Ruston L.; Lyne P.D.; Read J.A.; Peng X.; Pei X.; Fawell S.; Tang Z.; Throner S.; Vasbinder M.M.; Wang H.; Winter-Holt J.; Woessner R.; Wu A.; Yang W.; Zinda M.; Kettle J.G.; Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. J Med Chem 2020,63(9),4517-4527","journal-title":"J Med Chem"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.bmc.2019.02.054","volume":"27","author":"Yin Y.","year":"2019","unstructured":"Yin Y.; Chen C.J.; Yu R.N.; Shu L.; Zhang T.T.; Zhang D.Y.; Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold. Bioorg Med Chem 2019,27(8),1562-1576","journal-title":"Bioorg Med Chem"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"7596","DOI":"10.1021\/acs.jmedchem.5b01263","volume":"58","author":"Kim M.K.","year":"2015","unstructured":"Kim M.K.; Shin H.; Park K.S.; Kim H.; Park J.; Kim K.; Nam J.; Choo H.; Chong Y.; Benzimidazole derivatives as potent JAK1-selective inhibitors. J Med Chem 2015,58(18),7596-7602","journal-title":"J Med Chem"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/acsmedchemlett.6b00087","volume":"7","author":"Ritz\u00e9n A.","year":"2016","unstructured":"Ritz\u00e9n A.; S\u00f8rensen M.D.; Dack K.N.; Greve D.R.; Jerre A.; Carnerup M.A.; Rytved K.A.; Bagger-Bahnsen J.; Fragment-based discovery of 6-Arylindazole JAK inhibitors. ACS Med Chem Lett 2016,7(6),641-646","journal-title":"ACS Med Chem Lett"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1021\/acs.jmedchem.6b01634","volume":"60","author":"Jones P.","year":"2017","unstructured":"Jones P.; Storer R.I.; Sabnis Y.A.; Wakenhut F.M.; Whitlock G.A.; England K.S.; Mukaiyama T.; Dehnhardt C.M.; Coe J.W.; Kortum S.W.; Chrencik J.E.; Brown D.G.; Jones R.M.; Murphy J.R.; Yeoh T.; Morgan P.; Kilty I.; Design and synthesis of a Pan-Janus Kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory dis-eases of the lungs and skin. J Med Chem 2017,60(2),767-786","journal-title":"J Med Chem"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"9045","DOI":"10.1021\/acs.jmedchem.9b00533","volume":"62","author":"Bach J.","year":"2019","unstructured":"Bach J.; Eastwood P.; Gonz\u00e1lez J.; G\u00f3mez E.; Alonso J.A.; Fonquerna S.; Lozoya E.; Orellana A.; Maldonado M.; Calaf E.; Al-bert\u00ed J.; P\u00e9rez J.; Andr\u00e9s A.; Prats N.; Carre\u00f1o C.; Calama E.; De Alba J.; Calbet M.; Miralpeix M.; Ramis I.; Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) inhibitors for the inhaled treatment of respiratory diseases. J Med Chem 2019,62(20),9045-9060","journal-title":"J Med Chem"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1021\/acs.jmedchem.5b01857","volume":"59","author":"Yogo T.","year":"2016","unstructured":"Yogo T.; Nagamiya H.; Seto M.; Sasaki S.; Shih-Chung H.; Ohba Y.; Tokunaga N.; Lee G.N.; Rhim C.Y.; Yoon C.H.; Cho S.Y.; Skene R.; Yamamoto S.; Satou Y.; Kuno M.; Miyazaki T.; Nakagawa H.; Okabe A.; Marui S.; Aso K.; Yoshida M.; Struc-ture-based design and synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors. J Med Chem 2016,59(2),733-749","journal-title":"J Med Chem"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1021\/jm300438j","volume":"55","author":"Kulagowski J.J.","year":"2012","unstructured":"Kulagowski J.J.; Blair W.; Bull R.J.; Chang C.; Deshmukh G.; Dyke H.J.; Eigenbrot C.; Ghilardi N.; Gibbons P.; Harrison T.K.; Hewitt P.R.; Liimatta M.; Hurley C.A.; Johnson A.; Johnson T.; Kenny J.R.; Bir Kohli P.; Maxey R.J.; Mendonca R.; Mortara K.; Murray J.; Narukulla R.; Shia S.; Steffek M.; Ubhayakar S.; Ultsch M.; van Abbema A.; Ward S.I.; Waszkowycz B.; Zak M.; Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors. J Med Chem 2012,55(12),5901-5921","journal-title":"J Med Chem"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1021\/acs.jmedchem.9b01439","volume":"63","author":"Leonard K.A.","year":"2020","unstructured":"Leonard K.A.; Madge L.A.; Krawczuk P.J.; Wang A.; Kreutter K.D.; Bacani G.M.; Chai W.; Smith R.C.; Tichenor M.S.; Harris M.C.; Malaviya R.; Seierstad M.; Johnson M.E.; Venable J.D.; Kim S.; Hirst G.C.; Mathur A.S.; Rao T.S.; Edwards J.P.; Riz-zolio M.C.; Koudriakova T.; Discovery of a gut-restricted JAK inhibitor for the treatment of inflammatory bowel disease. J Med Chem 2020,63(6),2915-2929","journal-title":"J Med Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1021\/jm300628c","volume":"55","author":"Zak M.","year":"2012","unstructured":"Zak M.; Mendonca R.; Balazs M.; Barrett K.; Bergeron P.; Blair W.S.; Chang C.; Deshmukh G.; Devoss J.; Dragovich P.S.; Eigenbrot C.; Ghilardi N.; Gibbons P.; Gradl S.; Hamman C.; Hanan E.J.; Harstad E.; Hewitt P.R.; Hurley C.A.; Jin T.; Johnson A.; Johnson T.; Kenny J.R.; Koehler M.F.; Bir Kohli P.; Kulagowski J.J.; Labadie S.; Liao J.; Liimatta M.; Lin Z.; Lupardus P.J.; Maxey R.J.; Murray J.M.; Pulk R.; Rodriguez M.; Savage S.; Shia S.; Steffek M.; Ubhayakar S.; Ultsch M.; van Abbema A.; Ward S.I.; Xiao L.; Xiao Y.; Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. J Med Chem 2012,55(13),6176-6193","journal-title":"J Med Chem"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1021\/acs.jmedchem.8b00571","volume":"61","author":"Forster M.","year":"2018","unstructured":"Forster M.; Chaikuad A.; Dimitrov T.; D\u00f6ring E.; Holstein J.; Berger B.T.; Gehringer M.; Ghoreschi K.; M\u00fcller S.; Knapp S.; Laufer S.A.; Development, optimization, and structure-activity relationships of covalent-reversible JAK3 inhibitors based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold. J Med Chem 2018,61(12),5350-5366","journal-title":"J Med Chem"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1021\/acsmedchemlett.5b00226","volume":"6","author":"Wan H.","year":"2015","unstructured":"Wan H.; Schroeder G.M.; Hart A.C.; Inghrim J.; Grebinski J.; Tokarski J.S.; Lorenzi M.V.; You D.; Mcdevitt T.; Penhallow B.; Vuppugalla R.; Zhang Y.; Gu X.; Iyer R.; Lombardo L.J.; Trainor G.L.; Ruepp S.; Lippy J.; Blat Y.; Sack J.S.; Khan J.A.; Stef-anski K.; Sleczka B.; Mathur A.; Sun J.H.; Wong M.K.; Wu D.R.; Li P.; Gupta A.; Arunachalam P.N.; Pragalathan B.; Nara-yanan S.; K C, N.; Kuppusamy, P.; Purandare, A.V. Discovery of a highly selective JAK2 Inhibitor, BMS-911543, for the treatment of myeloproliferative neoplasms. ACS Med Chem Lett 2015,6(8),850-855","journal-title":"ACS Med Chem Lett"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1021\/jm300248q","volume":"55","author":"Dugan B.J.","year":"2012","unstructured":"Dugan B.J.; Gingrich D.E.; Mesaros E.F.; Milkiewicz K.L.; Curry M.A.; Zulli A.L.; Dobrzanski P.; Serdikoff C.; Jan M.; Ange-les T.S.; Albom M.S.; Mason J.L.; Aimone L.D.; Meyer S.L.; Huang Z.; Wells-Knecht K.J.; Ator M.A.; Ruggeri B.A.; Dorsey B.D.; A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: Dis-covery of CEP-33779. J Med Chem 2012,55(11),5243-5254","journal-title":"J Med Chem"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/cmdc.201700048","volume":"12","author":"Gunasekaran P.","year":"2017","unstructured":"Gunasekaran P.; Lee S.R.; Jeong S.M.; Kwon J.W.; Takei T.; Asahina Y.; Bang G.; Kim S.; Ahn M.; Ryu E.K.; Kim H.N.; Nam K.Y.; Shin S.Y.; Hojo H.; Namgoong S.; Kim N.H.; Bang J.K.; Pyrrole-based macrocyclic small-molecule inhibitors that target oo-cyte maturation. ChemMedChem 2017,12(8),580-589","journal-title":"ChemMedChem"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1021\/jm201454n","volume":"55","author":"William A.D.","year":"2012","unstructured":"William A.D.; Lee A.C.H.; Poulsen A.; Goh K.C.; Madan B.; Hart S.; Tan E.; Wang H.; Nagaraj H.; Chen D.; Lee C.P.; Sun E.T.; Jayaraman R.; Pasha M.K.; Ethirajulu K.; Wood J.M.; Dymock B.W.; Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2\/fms-like tyrosine kinase-3 (JAK2\/FLT3) for the treatment of rheumatoid arthritis. J Med Chem 2012,55(6),2623-2640","journal-title":"J Med Chem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026622666220307124142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/201825\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026622666220307124142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T12:33:25Z","timestamp":1691584405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/201825\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":155,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026622666220307124142","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}